Pages that link to "Q43248621"

The following pages link to Acute vardenafil administration improves bladder oxygenation in spontaneously hypertensive rats (Q43248621):

Displaying 36 items.

• Tadalafil for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a review of clinical data in Asian men and an update on the mechanism of action (Q26783529) (← links)
• The role of phosphodiesterase-5 inhibitors in prostatic inflammation: a review (Q26785428) (← links)
• Comparative effectiveness of oral drug therapies for lower urinary tract symptoms due to benign prostatic hyperplasia: a systematic review and network meta-analysis (Q28542960) (← links)
• Gelidium elegans Regulates the AMPK-PRDM16-UCP-1 Pathway and Has a Synergistic Effect with Orlistat on Obesity-Associated Features in Mice Fed a High-Fat Diet (Q33616651) (← links)
• Clinical correlates of enlarged prostate size in subjects with sexual dysfunction (Q34433316) (← links)
• Effect of the phytotherapeutic agent eviprostat on the bladder in a rat model of bladder overdistension/emptying (Q34473527) (← links)
• The role of phosphodiesterase type-5 inhibitors in treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia (Q35993920) (← links)
• PDE5-Is for the Treatment of Concomitant ED and LUTS/BPH. (Q37025381) (← links)
• The use of a single daily dose of tadalafil to treat signs and symptoms of benign prostatic hyperplasia and erectile dysfunction (Q37305843) (← links)
• Benign prostatic hyperplasia: a new metabolic disease of the aging male and its correlation with sexual dysfunctions. (Q37618958) (← links)
• Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: Pathophysiology and mechanism(s) of action (Q37833959) (← links)
• The role of phosphodiesterases in bladder pathophysiology (Q38106628) (← links)
• Management of benign prostatic hyperplasia: role of phosphodiesterase-5 inhibitors (Q38210468) (← links)
• Lower urinary tract symptoms, benign prostatic hyperplasia/benign prostatic enlargement and erectile dysfunction: are these conditions related to vascular dysfunction? (Q38220350) (← links)
• Opposite effects of tamoxifen on metabolic syndrome-induced bladder and prostate alterations: a role for GPR30/GPER? (Q39095837) (← links)
• Lower urinary tract symptoms/benign prostatic hypertrophy and vascular function: Role of the nitric oxide-phosphodiesterase type 5-cyclic guanosine 3',5'-monophosphate pathway (Q39195242) (← links)
• Are urge incontinence and aging risk factors of erectile dysfunction in patients with male lower urinary tract symptoms? (Q40341847) (← links)
• Influence of serum testosterone on urinary continence and sexual activity in patients undergoing radical prostatectomy for clinically localized prostate cancer. (Q40590766) (← links)
• The traditional Korean herbal medicine Ga-Gam-Nai-Go-Hyan suppresses testosterone-induced benign prostatic hyperplasia by regulating inflammatory responses and apoptosis (Q42059249) (← links)
• Sildenafil citrate in combination with tamsulosin versus tamsulosin monotherapy for management of male lower urinary tract symptoms due to benign prostatic hyperplasia: A randomised, double-blind, placebo-controlled trial (Q42319479) (← links)
• Mechanism of action of phosphodiesterase type 5 inhibition in metabolic syndrome-associated prostate alterations: an experimental study in the rabbit (Q43509817) (← links)
• Medicinal therapy of benign prostate syndrome with phosphodiesterase-5 inhibitors (Q43785753) (← links)
• Urodynamic improvements following oral medical therapy for partial bladder outlet obstruction in an animal model. (Q44140245) (← links)
• Tadalafil once daily in the treatment of lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) in men without erectile dysfunction (Q45216863) (← links)
• Editorial comment to postoperative phosphodiesterase type 5 inhibitor administration increases the rate of urinary continence recovery after bilateral nerve-sparing radical prostatectomy (Q46106331) (← links)
• Stimulators and activators of soluble guanylate cyclase for urogenital disorders (Q47603923) (← links)
• Effects of an alpha1A/D-adrenoceptor antagonist, naftopidil, and a phosphodiesterase type 5 inhibitor, tadalafil, on urinary bladder remodeling in rats with spinal cord injury. (Q47988536) (← links)
• Tadalafil for male lower urinary tract symptoms improves endothelial function (Q48717330) (← links)
• Neurohumoral regulation of spontaneous constrictions in suburothelial venules of the rat urinary bladder (Q50624749) (← links)
• PDE5 inhibitors blunt inflammation in human BPH: a potential mechanism of action for PDE5 inhibitors in LUTS. (Q50908802) (← links)
• Effects of the phosphodiesterase 5 inhibitor Tadalafil on bladder function in a rat model of partial bladder outlet obstruction. (Q51052878) (← links)
• Hemodynamic Effects of Once-daily Tadalafil in Men With Signs and Symptoms of Benign Prostatic Hyperplasia on Concomitant α1-Adrenergic Antagonist Therapy: Results of a Multicenter Randomized, Double-Blind, Placebo-controlled Trial (Q53135300) (← links)
• Effect of phosphodiesterase inhibitors in the bladder. (Q55101279) (← links)
• Editorial Comment to Tadalafil once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia: A randomized placebo- and tamsulosin-controlled 12-week study in Asian men (Q57582209) (← links)
• Treatment of the lower urinary tract symptoms secondary to benign prostatic hyperplasia by phosphodiesterase type 5 inhibitors. Review article (Q85205488) (← links)
• Microvascular dysfunction and efficacy of PDE5 inhibitors in BPH-LUTS (Q87424548) (← links)